Related references
Note: Only part of the references are listed.Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials
F. Khosrow-Khavar et al.
ANNALS OF ONCOLOGY (2017)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2017)
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2017)
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
Dimitrios Zardavas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity
Edith Pituskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Saro H. Armenian et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients
O. Aseyev et al.
CANCER RESEARCH (2017)
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
M. Martin et al.
ANNALS OF ONCOLOGY (2016)
Treatment with aromatase inhibitors and markers of cardiovascular disease
Eva Blondeaux et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Geeta Gulati et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A. Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
Pooja P. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Nadia Harbeck et al.
LANCET ONCOLOGY (2016)
Adaptive Randomization of Neratinib in Early Breast Cancer
J. W. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
Katharina Gunzer et al.
SPRINGERPLUS (2016)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial
Ahmad Awada et al.
JAMA ONCOLOGY (2016)
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Noam F. Ponde et al.
ESMO OPEN (2016)
ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity
Frances Belmonte et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
Sasha E. Stanton et al.
BMC CANCER (2015)
A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
Mothaffar F. Rimawi et al.
CLINICAL BREAST CANCER (2015)
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Claus Hanusch et al.
CLINICAL CANCER RESEARCH (2015)
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo) Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Chau Dang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Xavier Pivot et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Javier Cortes et al.
LANCET ONCOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Cardiotoxicity of anticancer treatments
Michael S. Ewer et al.
NATURE REVIEWS CARDIOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2014)
Cardiotoxicity of systemic agents used in breast cancer
Felipe Ades et al.
BREAST (2014)
New protein kinase inhibitors in breast cancer: afatinib and neratinib
Xiaosong Zhang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance)
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Past, Present, and Future Challenges in Breast Cancer Treatment
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer
Kathy D. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
Evandro de Azambuja et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al.
LANCET ONCOLOGY (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Ghideon Ezaz et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
A. Awada et al.
ANNALS OF ONCOLOGY (2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
L. W-C Chow et al.
BRITISH JOURNAL OF CANCER (2013)
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
Anne Polk et al.
CANCER TREATMENT REVIEWS (2013)
Cardiac MRI in the Assessment of Cardiac Injury and Toxicity From Cancer Chemotherapy A Systematic Review
Paaladinesh Thavendiranathan et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2013)
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer
Zhongzhen Guan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy
Paaladinesh Thavendiranathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E. Goss et al.
LANCET ONCOLOGY (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
Aman U. Buzdar et al.
LANCET ONCOLOGY (2013)
Anthracyclines and Heart Failure
Douglas B. Sawyer
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Sandra M. Swain et al.
ONCOLOGIST (2013)
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Manish Gupta et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G. Curigliano et al.
ANNALS OF ONCOLOGY (2012)
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2-a prospective study
Grzegorz Piotrowski et al.
ARCHIVES OF MEDICAL SCIENCE (2012)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Martin Schuler et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Nancy U. Lin et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Edward H. Romond et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
David Cameron et al.
ONCOLOGIST (2010)
Fluoropyrimidine-associated cardiotoxicity: revisited
M. Wasif Saif et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
Marc Spielmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer
Chia C. Portera et al.
CLINICAL CANCER RESEARCH (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
Neil L. Spector et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator
Tomasz Rudzinski et al.
EUROPACE (2007)
Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
Jack Cuzick et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy
Xifu Liu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Neuregulin activates erbB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes
Yukio Kuramochi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma - A prospectively planned combined survival analysis of two multicenter trials
A Howell et al.
CANCER (2005)
Adjuvant docetaxel for node-positive breast cancer
M Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Doxorubicin-induced second degree and complete atrioventricular block
S Kilickap et al.
EUROPACE (2005)
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial
A Decensi et al.
CIRCULATION (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
5-fluorouracil induces arterial vasocontractions
T Südhoff et al.
ANNALS OF ONCOLOGY (2004)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)